By Noimot Olayiwola/Staff Reporter
China-based Fuda Cancer Hospital, which claimed to be curing cancer through its innovative cutting-edge technique called the “CCC Treatment P Model (3C P)” is planning to establish a branch in Qatar thus bringing the treatment closer to its Middle Eastern clientele, it was learnt yesterday.
Profesor Xu during the interview at the Doha Sheraton yesterday
The hospital, which has formulated the unique cancer treatment 3C P with each C standing for cryosurgical ablation (CSA), cancer microvascular intervention (CMI) and combined immunotherapy for cancer (CIC) and the P standing for personalised cancer therapy (PCT), has up to June, received around 200 cancer patients from the Middle East .
While speaking to the Gulf Times yesterday, the centre’s general president Professor Kecheng Xu, who is in Doha on a short visit, explained that based on the condition of individual cancer patient, the centre is applying one or more of the three Cs to treat patients.
“We have achieved success beyond expectation through the use of breakthrough technology of combination of treatments like the 3C P model on none-resectable cancer patients who could not undergo surgical operation due to the advanced stage of their cancer and those who could not be treated by conventional methods or the recurrence of cancer,” he said.
He explained that the combination of several therapies in the treatment of cancer patients has become a special feature of Fuda hospital while claiming that more than 70% of patients admitted into the centre either has none-resectable tumours or they have been treated with chemotherapy and radiotherapy to no effect or they suffer from cancer relapse.
“Most of the patients we have treated in the past come in when their cancer was at an advanced stage, like in stage four or five and majority of them have been told by other medical facilities that they could not survive. But after they have been treated in our hospital, more than 70% of them experience significant improvement and their survival time has been prolonged, not by months but rather by years,” Fuda International Affairs director Esther Law explained.
According to her, many patients including those suffering from liver and lung cancer have lived more than five years with longest survival time of nine years.
She added that some patients having pancreatic cancer, which is being described as the king of cancer, even live for an additional 55 months.
Explaining each of the treatment method, Law said: “In CSA, we are using imaging guided technique such as ultrasound, computed tomography and magnetic resonance imaging by inserting cryo-probes repeatedly into the tumours to lower the temperature of the targeted area (up to 160 degree Celsius or below) leading to complete ablation of the whole tumour.”
“For CMI, also through image-guided micro-catheter, we insert tiny particles of some chemotherapy drugs through the wall of the tiny capillary vessels into the tumour to destroy the cancerous cells, while CIC is the combination of several immune techniques to increase or stimulate systemic immune function and this technique aims to raise and improve systemic immunological function of the cancer patients to help them fight against the cancer,” she explained.
“We are looking out for opportunities to collaborate with local health authorities here on our planned facility in Doha, which I believe will help alleviate the sufferings of many cancer patients and also save them the stress of making a long distance travel to China,” a Doha resident and also a consultant at the centre Dr S Tilib said.
He explained that talks were ongoing for possible co-operation with Qatari health authorities and senior officials at Hamad Medical Corporation’s Al Amal Hospital, the only cancer hospital in Qatar.
